- Email: [email protected]
Subject index volume 5
287
Subject index volume 5 Absorption, 85 Age, 105 Androstenedione, 245 Anion gap, 171 Atrophic vaginitis, 147 Autonomic nervous system, 17 Bereavement, 115 Blood, 171 Blood pressure, 135 Cervical mucus, 281 Ciliated cells, 39 Circulating oestrogens, 1 Citrate, 171 Climacteric, 105, 115, 153, 177, 201 263 Climacteric complaints, 233 Climacteric symptoms, 125 Climacteric syndrome, 207, 245 Clinical effects, 177 Clotting factors, 153 Conjugated oestrogens, 135, 147 Cyclic progestogen, 277 Depression, 17 Dose-response, 125 Double-blind study, 89 Duration, 207 E,-to-E, ratio, 85 Elderly men, 223 Electrical activity, 185 Endometrial biopsies, 89 Endometrial changes, 277 Endometrium, 281 EpitheliaI height, 39 Fatty acids, 263 Follicle-stimulating hormone, 31 FSH, 1 Gestagen, 9
HDL cholesterol, 77, 97, 193 Hormonal replacement therapy, 125 Hormonal substitution, 207 Hormone implants, 177 Hormones, 153 Hormone therapy, 97 Human oviduct, 185 Hysterectomy, 69 Instability, 17 Lactate, 171 LDL, 77 LDL-cholesterol, 193 LH bioactivity/immunoreactivity(B/I) ratio, 223 LH biological activity, 223 Life events, 115 Lipids, 153 Lipoproteins, 77, 271 Long-term therapy, 271 Luteinizing hormone, 31 Lynestrenol, 1 Menopause, 9, 25, 147, 171, 185 Mestranol, 271 Metabolic clearance rate, 251 Metabolism, 25 Microcrystalline, 85 Natural progesterone, 1 Norethisterone acetate, 85, 233 OD 14, 89, 281 Oestradiol, 31, 77, 85, 233 Oestradiol-serum levels, 177 Oestriol, 147, 233 Oestrogen, 9, 263, 277 Oestrogen-progestogen therapy, 201 Oestrogens, 25 Oestrogen therapy, 39 Oestrone, 85, 245
288
Oestrone sulphate, 135, 251 Opipramol, 17 Org OD 14, 89, 281 Overweight, 153 Percutaneous oestrogen, 1 Pituitary-ovarian relationship, 31 Post-menopausal, 97, 125 Post-menopausal hormone therapy, 259 Post-menopausal syndrome, 17 Post-menopausal women, 39, 193, 251 Pregnancy zone protein (PZP), 1 Pre-menopausal, 31 Prostacyclin, 201 Prostaglandin inhibitor, 263 Pyruvate, 171 Sequential oestrogen/progestogen treatment, 193
Sex hormone binding globulin (SHBG), 1 Skinfold thickness, 259 Social support, 115 Sodium, 25 Testosterone, 223 Thromboxane, 201 Thyroid, 105 Total cholesterol, 97 Triglycerides, 97 Triphasic, 233 Tubal epithelium, 39 Uric acid, 9 Vaginal cytology, 281 VLDL, 77 Withdrawal effects, 125 Women, 25, 171
Subject index volume 5 Absorption, 85 Age, 105 Androstenedione, 245 Anion gap, 171 Atrophic vaginitis, 147 Autonomic nervous system, 17 Bereavement, 115 Blood, 171 Blood pressure, 135 Cervical mucus, 281 Ciliated cells, 39 Circulating oestrogens, 1 Citrate, 171 Climacteric, 105, 115, 153, 177, 201 263 Climacteric complaints, 233 Climacteric symptoms, 125 Climacteric syndrome, 207, 245 Clinical effects, 177 Clotting factors, 153 Conjugated oestrogens, 135, 147 Cyclic progestogen, 277 Depression, 17 Dose-response, 125 Double-blind study, 89 Duration, 207 E,-to-E, ratio, 85 Elderly men, 223 Electrical activity, 185 Endometrial biopsies, 89 Endometrial changes, 277 Endometrium, 281 EpitheliaI height, 39 Fatty acids, 263 Follicle-stimulating hormone, 31 FSH, 1 Gestagen, 9
HDL cholesterol, 77, 97, 193 Hormonal replacement therapy, 125 Hormonal substitution, 207 Hormone implants, 177 Hormones, 153 Hormone therapy, 97 Human oviduct, 185 Hysterectomy, 69 Instability, 17 Lactate, 171 LDL, 77 LDL-cholesterol, 193 LH bioactivity/immunoreactivity(B/I) ratio, 223 LH biological activity, 223 Life events, 115 Lipids, 153 Lipoproteins, 77, 271 Long-term therapy, 271 Luteinizing hormone, 31 Lynestrenol, 1 Menopause, 9, 25, 147, 171, 185 Mestranol, 271 Metabolic clearance rate, 251 Metabolism, 25 Microcrystalline, 85 Natural progesterone, 1 Norethisterone acetate, 85, 233 OD 14, 89, 281 Oestradiol, 31, 77, 85, 233 Oestradiol-serum levels, 177 Oestriol, 147, 233 Oestrogen, 9, 263, 277 Oestrogen-progestogen therapy, 201 Oestrogens, 25 Oestrogen therapy, 39 Oestrone, 85, 245
288
Oestrone sulphate, 135, 251 Opipramol, 17 Org OD 14, 89, 281 Overweight, 153 Percutaneous oestrogen, 1 Pituitary-ovarian relationship, 31 Post-menopausal, 97, 125 Post-menopausal hormone therapy, 259 Post-menopausal syndrome, 17 Post-menopausal women, 39, 193, 251 Pregnancy zone protein (PZP), 1 Pre-menopausal, 31 Prostacyclin, 201 Prostaglandin inhibitor, 263 Pyruvate, 171 Sequential oestrogen/progestogen treatment, 193
Sex hormone binding globulin (SHBG), 1 Skinfold thickness, 259 Social support, 115 Sodium, 25 Testosterone, 223 Thromboxane, 201 Thyroid, 105 Total cholesterol, 97 Triglycerides, 97 Triphasic, 233 Tubal epithelium, 39 Uric acid, 9 Vaginal cytology, 281 VLDL, 77 Withdrawal effects, 125 Women, 25, 171